Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) has acquired 100% of the shares of Recipharm Israel Ltd., which operates a cGMP manufacturing site in Yavne, Israel, and simultaneously entered into a long-term strategic commercial collaboration with Recipharm. The transactions expand Scinai’s manufacturing
ProBioGen has introduced CMC Navigator™, a set of four defined CMC service models designed to support biopharmaceutical companies across key stages of protein Chemistry, Manufacturing and Controls (CMC) development. The framework is intended to help teams align scope, timelines, and
A once-niche manufacturing technology is going mainstream, as biopharma’s biggest players bet billions on replacing batch production with “always-on” continuous bioprocessing. According to Astute Analytica’s 2026 market report, the continuous bioprocessing market was valued at $319.77 million in 2025 and
Terumo Corporation has completed its acquisition of a drug product plant and quality control laboratory operations from WuXi Biologics in Leverkusen, Germany. The transaction officially closed on September 30, 2025. The acquisition expands Terumo’s position in the contract development and
Europe took a decisive step toward pharmaceutical sovereignty on January 21, when the European Parliament overwhelmingly approved the Critical Medicines Act. With 503 MEPs backing the proposal out of 668, the legislation now enters trilogue negotiations (three-way talks between Parliament,
Picture the scene: the Sales teams from a CDMO and Sponsor are delighted to have finalized the principles of a manufacturing deal, the relationship is off to a strong start, but now the dreaded ‘template’ is issued. Suddenly, everything comes
OneSource Specialty Pharma Limited has received approval from the Saudi Food and Drug Authority (SFDA) for its generic Ozempic® (semaglutide) in Saudi Arabia, enabling commercialisation in partnership with Hikma Pharmaceuticals PLC across the Middle East and North Africa (MENA) region.
The FDA officially launched its Manufacturing PreCheck Pilot Program on February 1, 2026, introducing a two-phase regulatory framework designed to accelerate construction and approval of new U.S. pharmaceutical manufacturing facilities. The initiative arrives as the contract development and manufacturing organization
Shilpa Medicare Limited (SML) has entered into a binding agreement with NXI Therapeutics AG, a Swiss-based company, to develop and manufacture a New Chemical Entity (NCE) targeting autoimmune and alloimmune disorders. The collaboration marks a step in Shilpa’s expansion within
Ampersand Capital Partners has acquired Purna Pharmaceuticals, a provider of development and manufacturing services for liquid and semi-solid dosage forms serving pharmaceutical industry customers. The transaction marks the next phase of growth for Purna and expands Ampersand’s life sciences portfolio.
